Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.35

0.0%

Nov 7 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (1073)	11/6/2001 2:58:07 PM
From: scaram(o)uche	Read Replies (2) of 1475

FWIW, and I apologize if this has been posted before.......... MedImmune also initiated two Phase I clinical studies of Vitaxin, an anti-angiogenic antibody optimized by AME and licensed to MedImmune, for rheumatoid arthritis and colorectal cancer. Message 16615300 I remember MEDI talking about plans for Vitaxin in RA, but I don't remember their having initiated a trial. Again, apologies if this has been posted. Not feeling warm and fuzzy. Again, the MEDI spin on the phase II psoriasis results? It is not (no "IMO" is necessary) consistent with the actual results from the very small multi-dose i.v. trial. I still feel that a single ego is getting in the way of a rational test of low dose 507 for autoimmunity. I am sincerely concerned that the antibody will be used at concentrations where T cell depletion is pronounced, without ever having sufficiently tested lower doses.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next